Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linezolid

Next Previous
Drug Profile

Linezolid

Alternative Names: L - Pfizer; Lin - Pfizer; PNU 100766; U 100766; Zyvox; Zyvoxam; Zyvoxid

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Acetamides; Antibacterials; Oxazolidinones; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Methicillin-resistant Staphylococcus aureus infections; Vancomycin-resistant enterococcal infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections; Community-acquired pneumonia; Diabetic foot ulcer; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Nosocomial infections; Nosocomial pneumonia; Skin and soft tissue infections; Vancomycin-resistant enterococcal infections

Most Recent Events

  • 25 Jun 2015 Pfizer terminates a phase III trial in Optic nerve disorders in USA, Italy and Sweden (NCT00359632)
  • 01 Jan 2014 Seoul National University Hospital initiates a phase II trial in Tuberculosis (pulmonary) in South Korea (NCT01994460)
  • 22 Oct 2010 Efficacy data from a phase IV trial (ZEPHyR) in Nosocomial pneumonia due to MRSA released by Pfizer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top